The depositary for the tender offer has advised GlaxoSmithKline (GSK) that shareholders of Genelabs have tendered and not withdrawn a total of approximately 39.25 million shares of Genelabs
ImQuest anticipates initiating its Phase I studies in the first quarter of 2009. IQP-0410 is a novel small molecule inhibitor of HIV which primarily acts as a nonnucleoside
The grant of the license follows the exercise by this top-tier global pharmaceutical company of the option (the ‘antibody option’) that it acquired from Intellect pursuant to an
Intradigm will use series B funds to advance its RNA interference therapeutics platform, which is comprised of both its siRNA intellectual property, as well as its proprietary delivery
With this clearance, the device may now be utilized during procedures of the skin, subcutaneous tissues and nasal passages, for applications in podiatry, dermatology, plastic surgery, and otolaryngology.
The first five patients in this 60-patient trial have already been enrolled. During the study’s initial cranial surgical procedures, the patients’ dura mater was successfully repaired by surgeons
As in previous trials, this study has reportedly demonstrated a clear dose response relationship with four out of the six treatment groups achieving statistically significant clearance of AK
According to the company, the trainer, code named ‘SEATD’ (Stock Emergency Airway Training Device), provides dynamic anatomical replication, enabling superior, realistic teaching and training scenarios for all surgical
The Phase II multi-center, double-blind, placebo-controlled trial will be conducted in the US and will evaluate the analgesic efficacy and safety of intravenous CR845 during the post-operative period
Under the terms of the agreement, Champions will use its Biomerk Tumorgraft preclinical platform to evaluate a combination therapy indication for Salirasib, a Ras antagonist. This agreement modifies
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.